Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
230.65B
Market cap230.65B
Price-Earnings ratio
12.29
Price-Earnings ratio12.29
Dividend yield
3.49%
Dividend yield3.49%
Average volume
12.87M
Average volume12.87M
High today
$95.08
High today$95.08
Low today
$91.15
Low today$91.15
Open price
$92.42
Open price$92.42
Volume
19.63M
Volume19.63M
52 Week high
$105.07
52 Week high$105.07
52 Week low
$73.31
52 Week low$73.31

Stock Snapshot

With a market cap of 230.65B, Merck(MRK) trades at $93.04. The stock has a price-to-earnings ratio of 12.29 and currently yields dividends of 3.5%.

As of 2025-11-16, Merck(MRK) stock has fluctuated between $91.15 and $95.08. The current price stands at $93.04, placing the stock +2.1% above today's low and -2.1% off the high.

The Merck(MRK)'s current trading volume is 19.63M, compared to an average daily volume of 12.87M.

During the past year, Merck(MRK) stock moved between $73.31 at its lowest and $105.07 at its peak.

During the past year, Merck(MRK) stock moved between $73.31 at its lowest and $105.07 at its peak.

MRK News

Simply Wall St 8h
Merck: Assessing Valuation After Recent Share Price Momentum and Pipeline Updates

Merck (MRK) shares traded close to flat today, holding steady as investors weigh recent performance and updates from the pharmaceutical sector. Despite minimal...

Merck: Assessing Valuation After Recent Share Price Momentum and Pipeline Updates
TipRanks 18h
Hold Rating on Merck & Company: Balancing Strategic Acquisitions and Future Growth Prospects

Merck & Company, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Terence Flynn from Morgan Stanley maintained a Hold ra...

TipRanks 23h
Eli Lilly, GM, IonQ, Merck, MARA: Insider Moves Unveiled!

Insiders have been trading these 5 stocks: ((LLY)), ((GM)), ((IONQ)), ((MRK)) and ((MARA)). Here is a breakdown of their recent trades and their value. Meet Yo...

Analyst ratings

57%

of 28 ratings
Buy
57.1%
Hold
42.9%
Sell
0%

More MRK News

Investopedia 2d
This Biotech's Stock Price More Than Doubled on Friday. Here's Why.

Close Key Takeaways Merck agreed to pay $9.2 billion to purchase Cidara Therapeutics, looking to cash in on the firm's experimental flu treatment. The $221.50...

This Biotech's Stock Price More Than Doubled on Friday. Here's Why.
Nasdaq 2d
Cidara Therapeutics Shares Soar 105% After Merck Agrees To $9.2B Takeover Deal

(RTTNews) - Cidara Therapeutics, Inc. (CDTX) climbed 105.68% to $217.99, up $112.00, after it announced that Merck & Co. will acquire all outstanding shares for...

Cidara Therapeutics Shares Soar 105% After Merck Agrees To $9.2B Takeover Deal
Investor's Business Daily 2d
Merck Swoops In On Buyout Bonanza With A $9.2 Billion Cidara Therapeutics Deal

Cidara Therapeutics (CDTX) shares doubled, and then some, on Friday after Merck (MRK) agreed to buy the biotech company for $9.2 billion. The deal is "nothing...

Merck Swoops In On Buyout Bonanza With A $9.2 Billion Cidara Therapeutics Deal
Benzinga 2d
Merck Makes Big Bet On Flu Protection With Cidara Buyout

Merck & Co. Inc. (NYSE:MRK) on Friday agreed to acquire Cidara Therapeutics, Inc. (NASDAQ:CDTX) for $221.50 per share in cash, for a total transaction value of...

Merck Makes Big Bet On Flu Protection With Cidara Buyout
TipRanks 2d
Morning Movers: Cidara skyrockets following Merck buyout offer

Stock futures are trading lower this morning as investors wrestle with a growing sense that the Federal Reserve may not cut interest rates in December or at lea...

The Wall Street Journal 2d
Merck to Buy Cidara Therapeutics in $9.2 Billion Deal

Merck & Co. has struck a $9.2 billion deal to buy biotechnology company Cidara Therapeutics in a move that bolsters the drugmaker’s respiratory portfolio and pi...

Merck to Buy Cidara Therapeutics in $9.2 Billion Deal
Nasdaq 2d
Merck To Acquire Cidara For $221.50/shr

(RTTNews) - Merck (MRK) and Cidara Therapeutics, Inc. (CDTX) have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cida...

Merck To Acquire Cidara For $221.50/shr

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.